Navigation Links
CardiacAssist, Inc. Announces Five New TandemHeart Centers of Excellence
Date:4/18/2008

PITTSBURGH, April 18 /PRNewswire/ -- CardiacAssist, Inc. announced that it has placed the TandemHeart System at five new medical centers. More than 100 hospitals worldwide now use the TandemHeart System in the Cath Lab and/or Operating Room for extracorporeal circulatory support.

The five new TandemHeart Centers of Excellence are:

-- Advanced Perfusion Care, Pinehurst, NC

-- Provena St. Joseph Medical Center, Joliet, IL

-- Sarasota Memorial Hospital, Sarasota, FL

-- St. Joseph Hospital of Atlanta, Atlanta, GA

-- Temple University Hospital, Philadelphia, PA

The TandemHeart System provides extracorporeal circulatory support through a percutaneous cardiac catheterization procedure or direct surgical placement in as little as 30 minutes. The resulting increase in blood flow is up to five liters per minute percutaneously or 8 LPM via surgical cannulation.

"We're pleased to have such prestigious cardiac care facilities join our centers of excellence that are now using the TandemHeart System," said Michael Garippa, President and CEO of CardiacAssist, Inc. "The adoption rate for this technology continues to increase, and our commercial experience with the TandemHeart is on the way to 2,000 cases."

Advanced Perfusion Care, Inc. provides quality, comprehensive perfusion and auto transfusion services to hospitals throughout the United States. In 2008, Provena St. Joseph Hospital received a Distinguished Hospital Award for Clinical Excellence from Healthgrades. Sarasota Memorial Hospital is ranked among the Top 50 Community Hospitals as determined by U.S. News and World Report 2007. Temple University Medical Center is one of the premier academic hospitals in the nation and consistently ranks among the nation's top hospitals in the U.S. News & World Report's guide to "America's Best Hospitals." Saint Joseph's Hospital of Atlanta is a leader among Georgia health-care providers, respected for its expertise, in
'/>"/>

SOURCE CardiacAssist, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...mmune response after antiretroviral therapy may be... 25 (HealthDay News) -- A new study challenges the... impairs the immune system,s ability to restore it...tive antiretroviral therapy (HAART). , From 50 ...re also infected with HCV. Intravenous drug use is...
(Date:7/25/2008)..., July 25 /PRNewswire/ -- BeaconEquity.com announc...ng news today., Investors can view all of the dai...conEquity.com/m , Today,s Trade Alerts include: D...rook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMe... ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis In...
(Date:7/25/2008)...Relationship Based on Significant Improvements in ... MDdatacor, Inc., a leader in health,care quality ...s, today,announced it has entered into a long-term...ort Wellmark,s Collaboration on Quality(SM) Incent...tion between Wellmark and,primary care clinicians ...
(Date:7/25/2008)...AD, Calif., July 25 /PRNewswire/ -- AutoGenomics, ...ion statement on Form S-1 with the,Securities and ...al public,offering of shares of its common stock. ..., all of which are expected to be offered by,AutoG...g, have not yet been,determined., J.P. Morgan Sec...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...ios Spanos was shocked when his doctor discovered ... his body’s largest blood vessel, the aorta, durin...o symptoms, and was relieved to find out that the ...had been caught while it was still small. For the...
... A brewery in Japan launched production of unusual...farmer who was looking for ways to put his milk su...k will be available in the store shelves Thursday,...akashibetsu, on the country's northernmost island ...
... are planning to whiten your teeth by bleaching th...it done by unqualified people could cause consider...alons are offering teeth whitening by unqualified ...l bleach," said Christopher Orr, president of the ...
...tors and nurses who work in the developing world w...challenges, according to ‘Meeting the Health needs... The BMA’s International Committee surveyed 79 UK...including 67 doctors, who had recently worked in A...
Other Medicine News:Health News:Early Detection of Artery Weakening Can Be a Life-Saver 2Health News:Early Detection of Artery Weakening Can Be a Life-Saver 3Health News:Health Workers Need Better Preparation for Developing World 2
(Date:7/22/2008)...test awards under Therapeutics Development Initiat...tions to 23; next deadline January 20,2009, NEW ...f its mission to,speed delivery of transformative ... Michael J. Fox Foundation for Parkinson,s Researc... industry research teams. The awards,were granted ...
(Date:7/22/2008)... Regimens Including Lantus(R) and Apidra(R) Result...ith Type 2 Diabetes, Whatever the Algorithm ...., July 22 /- Results from the "Adjus...mple Algorithm to Carbohydrate,Counting for Adjust...blished in the American Diabetes Association,s (AD...
(Date:7/22/2008)...eveloped and Validated by Columbia University Medi...oprietary MicroRNA Technology, The Test Differen...ung Cancer (NSCLC), Classifying Squamous-Cell Car...ercent and Specificity of 90 Percent,This is the F... Sensitivity as Biomarkers for Accurate D...
(Date:7/22/2008)...lot Study Suggests That Ekkyo,s New Approach of LA...ly Improve Scar Healing Physiology, MARSEILLES, F...wn as,Heatwave Technology) a photomedicine company...s for skin scar prevention and reduction, announce... Lasers in Surgery and Medicine*,reporting the res...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Avantium and BP Extend Strategic Partnership 3782 1Avantium and BP Extend Strategic Partnership 3782 2ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 1ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 2ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 1Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 2
... Useful in Cancer Treatment,Decisions , SALT LAKE ...ASDAQ: MYGN) (<a target="_blank" href=,"http://www...t,it presented studies for a new technology that m... a metastatic tumor, on Monday,April 16, 2007 at ... Cancer Research (AACR) in Los Angeles, California...
...r 19, 2007 - Antares Pharma, Inc.,(AMEX: AIS) anno...ite application study demonstrating that ANTUROL(R...sorbed on a bioequivalent,basis after a single-dos...ns., The study was an open-label, comparative thre...study. The trial enrolled 25,healthy subjects (80%...
Other Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3
...y Biotech Captia™ Varicella- Zoster Virus (VZV...s intended for the detection and quantitative dete...dividual serum specimens may be used for the deter...convalescent, may be used to demonstrate seroconve...
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as
The Trinity Biotech Mumps IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the qualitative detection of IgM antibody in human serum to Mumps for the determination of immunological experi
The DIAGNOSTIC AUTOMATION, INC. (DAI) Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection and quantitative determination of IgG antibody to Mumps virus in human sera. In
Medicine Products: